EGFR and colorectal carcinoma: More recently with logistic regression models, including the miR-31-3p expression level adjusted for potential confounding factors, Laurent-Puig et al. (2019) validate the use of miR-31-3p to differentiate RAS wt metastatic CRC patient outcomes from patients treated with anti-EGFR mAb or anti-VEGF mAb therapy.